- Home
- NAZ vs AGEN Comparison
NAZ vs AGEN Comparison
Compare NAZ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAZ
- AGEN
- Stock Information
- Founded
- NAZ 1992
- AGEN 1994
- Country
- NAZ United States
- AGEN United States
- Employees
- NAZ N/A
- AGEN N/A
- Industry
- NAZ Finance/Investors Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAZ Finance
- AGEN Health Care
- Exchange
- NAZ Nasdaq
- AGEN Nasdaq
- Market Cap
- NAZ 145.2M
- AGEN 126.8M
- IPO Year
- NAZ N/A
- AGEN 2000
- Fundamental
- Price
- NAZ $11.85
- AGEN $4.29
- Analyst Decision
- NAZ
- AGEN Buy
- Analyst Count
- NAZ 0
- AGEN 2
- Target Price
- NAZ N/A
- AGEN $14.50
- AVG Volume (30 Days)
- NAZ 18.3K
- AGEN 460.1K
- Earning Date
- NAZ 01-01-0001
- AGEN 11-10-2025
- Dividend Yield
- NAZ 3.69%
- AGEN N/A
- EPS Growth
- NAZ N/A
- AGEN N/A
- EPS
- NAZ N/A
- AGEN N/A
- Revenue
- NAZ N/A
- AGEN $106,829,000.00
- Revenue This Year
- NAZ N/A
- AGEN $60.49
- Revenue Next Year
- NAZ N/A
- AGEN N/A
- P/E Ratio
- NAZ N/A
- AGEN N/A
- Revenue Growth
- NAZ N/A
- AGEN N/A
- 52 Week Low
- NAZ $9.22
- AGEN $1.38
- 52 Week High
- NAZ $11.37
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- NAZ 47.75
- AGEN 54.02
- Support Level
- NAZ $11.77
- AGEN $4.17
- Resistance Level
- NAZ $11.95
- AGEN $4.60
- Average True Range (ATR)
- NAZ 0.15
- AGEN 0.28
- MACD
- NAZ -0.01
- AGEN 0.04
- Stochastic Oscillator
- NAZ 30.49
- AGEN 61.32
About NAZ Nuveen Arizona Quality Municipal Income Fund
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).